Introduction
Carcinogenesis is a disease process in which cells accumulate multiple genetic and epigenetic events which lead to the phenotype of cancer. The involvement of multiple events complicate biological studies of carcinogenesis; however, this problem is somewhat simpli®ed by the availability of models which require only a limited number of events to produce cancer. An important, well-studied, but still controversial, model of this latter type is that of rodent carcinomas induced by the expression of the mutated/activated neu oncogene in mammary parenchyma. This was ®rst accomplished by Muller et al., (1988) who introduced neu into transgenic mice under the control of the MMTV LTR promoter (Muller et al., 1988) . In one line of mice, mammary carcinomas arose synchronously and involved the entire mammary parenchyma. This observation was interpreted as an unique example of a single-step process of carcinogenesis. In other words, it was suggested that neu is fully penetrant genetically. In contrast, using similar constructs, Bouchard et al. (1989) produced several lines of transgenic mice, all of which developed mammary carcinomas at relatively lower frequencies in a stochastic manner. These latter observations were interpreted to suggest that neu expression was only a single-step in a multistep mammary carcinogenesis process. Dierences in the propensity for mammary cancer development in these strains were postulated to arise from strain-speci®city and/or positional eects of dierential genomic integration of the transgene.
To extend these studies in an experimental model in which positional eects are minimized by averaging, we introduced activated neu into rat mammary parenchymal cells using replication-defective retroviral vectors which were infused into the milk lumen of the rat mammary gland. When viruses at high titer were infused, which resulted in infection of approximately 0.3% of mammary epithelial cells, we observed an extremely high frequency of mammary carcinomas arising both rapidly and synchronously in a fashion (Wang et al., 1991a) resembling the neu-transgenic observations of Muller et al. (1988) . These results led us to test the hypothesis suggested by Muller that neu was capable of transforming mammary cells by a single-step mechanism. This hypothesis was ®rst challenged by our ®ndings that hormonal manipulation of rats could increase the mammary tumor yield in neu-vector infused rats (Tai and Gould, 1995) . This ®nding is not compatible with neu being fully penetrant under normal physiological conditions. In order to address this hypothesis quantitatively, here we measured the probability with which activated neu can fully transform mammary epithelial cells. To our knowledge, this is the ®rst time the genetic penetrance of an activated oncogene has been quaniti®ed in vivo. While many previous in vivo transgenic and in vitro transfection studies have qualitatively estimated the relative potency of several oncogenes (Land et al., 1983; Stewart et al., 1984; Lee et al., 1985; Matsui et al., 1990; Cardi et al., 1991) , they did not quantify their transformation potency. Such a quantitative estimate is needed to better place an oncogene activation into the context of multistage carcinogenesis and to begin to characterize the nature of events required to complement oncogene activation for progression to neoplasia. The genetic penetrance of neu was measured here by ®rst introducing neu into mammary cells in situ using retroviral vectors and then using a quantitiative limiting dilution transplantation assay to quantify both the percentage of clonogenic cells expressing neu and the percentage of clonogens which progress to form mammary carcinomas. Our results suggest that neu is very highly penetrant.
Results

Clonogenic frequency of pJRneu-infected mammary cells
Monodispersed mammary cell suspensions from donor pJRneu-infused and control rats were prepared and serially diluted for cell transplantationclonogenic assays. The clonogenic fraction of mammary cells which were infected by pJRneu retroviruses in situ and that of control mammary gland cells were compared (Figure 1 ). The MD 50 for the control group is 760 cells, whereas that for the pJRneu-treated group is 597 cells. This converts to a frequency of viable clonogenic stem-like cells in the control cell suspension of 1 of 1095, whereas that in the pJRneu-infected cell suspension is 1 in 861. There is no statistically signi®cant dierence between these two values (P=0.691), suggesting that the frequency of viable clonogenic (stem-like) cells is not altered by infection with pJRneu replication-defective retrovirus.
Evaluation of the sensitivity of detection of pJRneu
A PCR/Southern based screening was developed to monitor the presence of integrated pJRneu in both the infected mammary cells and tissues developing from transplants of infected mammary clonogenic cells. This PCR/Southern methodology is consistently able to detect the presence of pJRneu-infected cells at a level of 0.001% in a mammary cell suspension (Figure 2 ). This degree of sensitivity was also obtained with a second pair of primers which ampli®ed the neo fragment in pJRneu (Figure 2 ). By comparison of the intensity of bands for experimental samples with those of the PCR reactions of serial dilution of DNA standards, the infection frequency of mammary cells by pJRneu, at a titer of 3610 7 CFU/ml, is estimated to be within a range of 0.1 ± 0.5% (Figure 2 ).
The penetrance of neu in transformation of rat mammary cells
Using a modi®ed limiting dilution mammary clonogenic cell transplantation assay, the frequency of pJRneu-containing clonogenic cells was quanti®ed. The percentage of graft sites positive for pJRneu by PCR/Southern analysis was plotted against the number of injected clonogenic cells, and a PCR 50 value of 127 cells was derived (Figure 3) . Thus, 1 out of 182 clonogen cells were estimated to have stable integrated pJRneu. An average of 750 clonogens (*7.5610 5 cells) prepared from pJRneu-infused mammary glands were transplanted into each graft site of 82 isologous hormonally promoted recipients and tumor induction in the graft sites was followed for 6 months. Twentyseven tumors developed in the graft sites at the end of this time period. Twenty-four of them were histopathologically identi®ed as carcinomas. Thus 1 out of 5125 grafted clonogenic cells progressed to a mammary carcinoma.
Combining those ®ndings that 1 out of 182 mammary clonogens have integrated pJRneu and 1 out of 5125 clonogens progressed to a carcinoma at the graft site, provides an estimate of the probability that a neu-expressing clonogenic cell will yield a carcinoma. Thus, [(1/5125)/(1/182)] or 1 in 28 (95% con®dence interval: 1 in 17, 1 in 44) pJRneu-containing mammary clonogens progessed to form mammary carcinomas. Therefore, the genetic penetrance of neu for transforming mammary cells is estimated to be 3.6%.
RNA expression of mammary tissue growth and tumors in graft sites
RT ± PCR reactions were conducted for 15 randomly selected pJRneu-infected normal mammary tissue grafts in order to evaluate the expression of pJRneu. The relative level of pJRneu RNA expression was quanti®ed using a competitive RT ± PCR assay as shown in Figure 4 . All 15 samples of normal mammary tissue at the graft sites showed an equivalent expression of message from pJRneu following normalization using external and internal controls.
Carcinomas in graft sites all have pJRneu mRNA expression ( Figure 5 ). Interestingly, normal mammary tissues surrounding these tissues did not have detectable vector RNA transcripts. In addition, three tumors that were not classi®ed as carcinomas did not contain and express pJRneu. Figure 6 showed the histopathology of a carcinoma that developed at one of the graft sites.
Discussion
We have estimated the genetic penetrance of the activated neu oncogene to be approximately 3.6% with respect to its ability to neoplastically transform rat mammary clonogenic (stem-like) cells in vivo. To our knowledge, this represents the ®rst direct quanti®cation of the genetic penetrance of an oncogene in an in vivo mammalian setting. It is stressed that this estimate of penetrance is likely model speci®c. The activation of neu in this model is by a point mutation in the transmembrane domain. This contrasts neu activation in human mammary carcinomas in which activation is by overexpression of wild type neu. Interestingly, this frequency of 3.6% of neu-infected cells progressing to a carcinoma is compatible with the semi-quantitative data obtained for the transformation of in situ mammary cells by infection with this same vector. When mammary glands were infused with pJRneu vector at a titer of 2.5610 5 CFU/ml and maintained under a similar hormonal state as used in the current experiment, each rat developed an average of 3.9 carcinomas (Tai and Gould, 1995) . The frequency of infection in this experiment can be estimated by extrapolating from an equivalent infusion study using b-gal containing retroviral vectors. When a pJR-b-gal reporter vector was used for mammary infusion at a titer of 5610 7 CFU/ml, 0.3% of cells were functionally infected. It thus can be estimated by extrapolation that 300 of the estimated 2610 7 mammary cells of a rat were infected with pJRneu in the above-referenced in situ transformation experiment. Together, these observations provide a rough estimate that 1 in 77 (1.3%) neu-infected cells progress to cancer. This estimated penetrance of 1.3% is in the same range of the direct measurement of genetic penetrance from the current study of 3.6%. The threefold dierence in values may be due to the inexact estimate of either total mammary cells per rat or infection rates extrapolated from a b-gal reporter assay. Importantly, even if this threefold dierence is real, it does not approximate the 500-to 1000-fold dierence between the number of total mammary epithelial cells per rat and those of a subpopulation of these cells which are assayed to be stem-like clonogens. Clonogens are de®ned as mammary cells which, upon transplantation, can clonally form complete mammary tissue (Clifton and Gould, 1985) . These results, which demonstrate a similar genetic penetrance of pJRneu in both a population of total mammary epithelial cells and a subpopulation of mammary clonogens, suggest that both populations are transformation targets with similar propensities for neu-mediated neoplastic conversion. Whether they are equivalent targets for transformation by other agents will require further investigation.
Our studies, however, have several limitations which prevent us from completely rejecting a one-step model of transformation. In other words, while our estimate of neu genetic penetrance does not statistically overlap 100%, possibilities exist in which our measurement of neu penetrance could be compatible with neu being fully penetrant. Alternatively, neu in its native con®guration could be less penetrant than was estimated in our system. The latter possibility could arise from the fact that in our model neu expression is controlled by a strong viral promoter which results in greater levels of neu than would be expected from its endogenous promoter. Such overexpression could theoretically lead to an increase in genetic penetrance.
The former possibility that the true penetrance of neu could be greater than we estimated could arise from a potential heterogeneity in our clonogenic cell population. If such a situation existed then it would be possible that neu could be fully penetrant in a subpopulation of clonogens and poorly or nonpenetrant in the remainder of clonogenic cells resulting in an average penetrance of 3.6%. In addition to this possibility, other situations can be postulated to suggest that our measured genetic penetrance of 3.6% could be compatible with the possibility that every neuinfected clonogen is fully transformed despite the fact that only 3.6% progress to cancer. These include the possibility that: (1) most transformed cells or their progeny are prevented from forming tumors due to immune surveillance (Shemesh and Ehrlich, 1993; Bauer, 1996) or programmed cell death (Hess and Engelmann, 1996; Langer et al., 1996; Lenahan and Ozer, 1996) , or (2) since the neu-infected clonogens are grafted together with normal cells, a potential for normal cells to inhibit the growth or progression of transformed cells exists. Such an inhibition of radiation-initiated cells has recently been demonstrated by Kamiya et al. (1995) who showed that normal cells could repress the progession of initiated cells by a factor of at least tenfold. A similar magnitude of inhibition could convert a potential penetrance of 100% to less than 10%.
Each carcinoma that developed at an individual graft site had very similar levels of neu RNA expressed from a single retroviral neu gene insertion. In contrast, no neu expression could be detected in adjacent normal tissue in spite of the fact that many neu infected nontransformed cells were estimated to be present in this tissue. Thus a question exists as to why neu expression can be detected in tumor but not normal tissue. Since each graft site received approximately four infected clonogens, it is possible that only one in four infected cells stably expressed sucient neu to transform its host cell. Such a possibility would be consistent with neu being fully penetrant when highly expressed. An alternative explanation for this observation should also be considered. Most rats in this study were necropsied at 6 months post transplantation. Based on previous data from which mammary cells were infected with retrovirus expressing b-gal, it is likely that most b-gal expression would be expected to be lost in infected cells 6 months post infection (Wang et al., 1991a) . This observation is compatible with other retroviral gene transfer experiments in which the activity of the inserted gene is rapidly lost following in vivo expression. Thus, our observation of lack of neu Figure 6 Histopathology of mammary tumors developing at graft sites. Tumor tissues were ®xed and stained with hematoxylin and eosin. An example of adenocarcinoma surrounded by normal mammary tissues expression in normal cells might be expected. In contrast, the stability of expression of retroviral inserted neu in these carcinomas is not predicted based on observations of the lack of stability of expression of retroviral inserted genes in normal cells. Thus either tumor developed from one in four cells which have stabilized expression or neoplastic transformation stabilized the expression of the inserted neu gene. The latter is a possibility since during neoplastic transformation many attributes of normal cells are lost or altered. If indeed tumors stabilize retroviral transferred gene expression, an understanding of this process could be important in the improvement of gene therapy by providing insight into factors extending the time period of retrovirally inserted gene expression.
If one assumes that activated neu in this retroviral model truly has a penetrance of 3.6% then it is likely complemented by a single additional transformation event (two-step carcinogenesis). The second step must then have a frequency in a population of target mammary cells of approximately 3.6%. Alternatively, if neu is complemented by two or more events, then each of their frequencies would even be higher in that their product would equal 3.6%. Such high event frequencies would likely exclude somatic cell-speci®c locus mutagenesis in that such a mutagenic event would have a frequency in mammalian cells of many orders of magnitude above the predicted event frequency of 3.6%. Such arguments extend not only to oncogenes and suppressor genes but also tò mutator' genes. It is thus possible to speculate that the complementing events are more global than speci®c locus mutations and are compatible with a variety of epigenetic heritable events. Examples include heritable events which may disregulate gene expression such as changes in DNA-methylation, chromatin con®guration and signal transduction. Interestingly, mammary carcinomas induced by pJRneu are not exceptionally genetically unstable. The overall level of allelic imbalance as measured by microsatellite marker loss, gain, or change of size is no dierent in these tumors than in those induced by the chemical carcinogens DMBA or NMU (Tai, Haag, and Gould, unpublished) .
The importance of epigenetic events in the carcinogenesis process if supported by several recently published observations. For example, mice de®cient in their ability to methylate DNA have been shown to have an increased frequency of colon adenomas when carrying the Apc min allele (Laird et al., 1995) . Additional indirect evidence for the initiation stage of carcinogenesis being epigenetic following radiation or chemical carcinogen exposure of the rat mammary gland derives from the observation that the cellular initiation frequency of carcinogenesis from these two agents is approximately 1%. In other words, 1 in 100 carcinogen-exposed mammary clonogenic cells will progress to a carcinoma (Domann et al., 1994; Kamiya et al., 1995) .
If indeed, our speculation that neu in this speci®c model is complemented by one or more high frequency epigenetic events is correct, it is important to determine if this oncogene is an exceptional case or whether this argument be extended to other oncogenes. The only oncogene other than neu for which we can estimate genetic penetrance in vivo is v-Ha-ras.
Using a similar retroviral model, we have previously shown that neu is relatively 200 times as penetrant as ras by introducing both into rat mammary cells in situ and quantifying the ratio of resulting carcinomas (Wang et al., 1991b) . Since it is now estimated that neu has a penetrance of 3.6%, we may estimate the penetrance of v-Ha-ras to be *1.8610
74
. While events with this frequency may be compatible with epigenetic events, this estimate does not rule out genetic basis for a second event such as a speci®c locus mutation. Such high frequency genetic events could result from a speci®c locus mutation in one of a large series of potential target loci or alternatively in a smaller series of loci which contain hot spots for mutagenesis. Again, this estimate of ras penetrance has similar limitations as discussed above for neu.
In summary, we have shown that 3.6% of mammary clonogenic cells that express mutated neu from a retroviral vector progress to form mammary carcinomas. This degree of penetrance estimated is very high but compatible with a multiple step neu transformation model. As discussed above, in certain circumstances this measured penetrance could also be compatible with a neu single-step transformation model.
Materials and methods
Retrovirus vector production and virus infusion
The construction and production of pJRneu retroviral vectors were detailed previously (Wang et al., 1991a) . pJRneu plasmid DNA was transfected into the cCRE ecotropic packaging cell line. Transiently expressed replication-defective viruses were collected and used to infect PA317 amphotropic packaging cells. Colonies of infected PA317 cells were selected by resistance to G418 (GIBCO, Bethesda, MD), and the virus titers were determined in NIH3T3 cells. High-producing clones were expanded for the mass production of viruses. Viruses were concentrated *100-fold by ultracentrifugation through sucrose in a Beckman SW28 rotor at 48C at 22 000 r.p.m. for 2 h. Concentrated viral aliquots were stored at 7808C.
Intraductal (i.d.) infusion of virus into rat mammary central ducts was accomplished using a 27-gauge blunt-ended needle. Each individual gland (12 glands/rat) was infused with 15 ml of a viral suspension. Two days before the infusion, rats were pretreated daily with an indirect mammary mitogen perphenazine (3 mg/kg, Sigma Chemical Co, St Louis, MO) to maximize stable virus incorporation. Immediately before mammary infusion, polybrene (80 mg/ml) and tracking dye Indigo carmine (2 mg/ml) were mixed with the concentrated viral aliquots. pJRneu vector at the highest titer achieved by these methods (*3610 7 CFU/ml) was used for infusion throughout.
Animals
Virgin female rats of the Wistar-Furth strain (WF, Harlan Sprague-Dawley, Madison, WI), 7 ± 8 weeks old at the time of virus infusion and mammary cell transplantation, were used throughout. Rats which were hormonally manipulated by pituitary implantation and adrenalectomy were given their choice of acidi®ed tap water or saline and were also injected subcutaneously with 2.5 mg deoxycorticosterone weekly. Rats with intact adrenals were maintained on acidi®ed tap water.
For the short-term assays of clonogenic mammary cell frequency, which lasted three and a half weeks, MtT W10 mammotropic pituitary tumors (Gould and Clifton, 1977) were grafted into hind legs of recipients at the time of mammary cell transplantation. This grafting results in high levels of circulating prolactin.
Mammary cell transplantation
Control and pJRneu-infected mammary cell suspensions were prepared for transplantation by methods we have previously reported (Clifton and Gould, 1985) . Brie¯y, the rats were killed, the lymph node chains were surgically cleared from the mammary glands, and mammary tissue was collected. Mammary glands were minced and were then enzymatically monodispersed with collagenase (Worthington; type III, 200 mg/ml) for 2 h, followed by DNase (Sigma; 7.5 units/ml) for 10 min at 378C. Next they were washed, resuspended in 0.05% trypsin (GIBCO, Bethesda, MD): 0.02% EDTA (Sigma Chemicals, St Louis, MO) in DMEM for 10 min. The resulting tissue digests were ®ltered through 53 mm nylon mesh and the ®ltrate was washed and resuspended in DMEM. The resulting cell suspensions, consisting of a heterogeneous mixture of mammary gland monodispersed cells, were counted for morphologically intact cells using phasecontrast microscopy. The desired dilutions of this cell suspension were mixed with an equal volume of a 50% rat brain homogenate, which increases transplantation efficiency (Gould and Clifton, 1977; Clifton and Gould, 1985) . Aliquots of 0.06 ml were used for each injection into the intrascapular white fat pads of isologous recipients.
Clonogen number
MD 50 is de®ned as the number of cells required to produce at least one mammary growth in 50% of the graft sites. MD 50 assays were performed on mammary cell suspensions from pJRneu-infused and control rats. MD 50 was calculated by methods previously described (Clifton and Gould, 1985; Clifton et al., 1986) . The viable clonogenic (stem-like) fraction in the mammary cell suspension was calculated from the MD 50 using the following equation: clonogenic frequency = MD 50 /0.693 (Clifton and Gould, 1985; Clifton et al., 1986) .
Three to four perphenazine-treated donor rats (Wang et al., 1991b) were infused in situ with pJRneu at day 0. Two days after infusion, monodispersed infected mammary cells were prepared for a limiting dilution cell transplantation assay. Mammary cell suspensions were injected into interscapular white fat pads (two graft sites per rat) of MtT W10 prolactin secreting pituitary tumor grafted recipient rats. There were eight rats for each dilution group and 10 cell dilutions were evaluated in each assay. Twenty-one to twenty®ve days after cell inoculation, rats were killed and fat-pad graft sites were removed, ®xed, and stained to evaluate mammary tissue growth. Each whole amount was scored for the presence or absence of mammary tissue. The percentage of graft sites with mammary growth was plotted against injected cell number per site and the clonogenic frequency was determined.
pJRneu-infected clonogen number
A modi®cation of an in vivo limiting dilution mammary clonogen transplantation assay was developed to estimate the frequency of pJRneu-infected clonogens in a mammary cell suspension. Ten donors of pJRneuinfused rats were used 2 days post infusion to prepare a monodispersed mammary cell suspension. Based on the clonogen number derived from the MD 50 for pJRneuinfected mammary cell suspension, six grafted clonogen concentrations were chosen and grafted into the interscapular fat pat of 18 recipients (two graft sites per rat) for each clonogen concentration to be assayed.
The number of cells chosen for injection was based on a dilution series centered on the middle dilution having approximately one infected cell assuming a 0.5% infection frequency. All cell dilutions were of sucient cell number to assure grafting of mammary tissue at each site. A PCR (polymerase chain reaction) based screening, described below, was used to determine if a graft site had received at least one clonogen that had stably integrated pJRneu. Sites receiving at least one clonogenic cell with pJRneu at grafting would likely have at least several thousand daughters cells by harvest (3 1 weeks post-transplantation). DNA was extracted from each mammary growth site and assayed by PCR and Southern analyses as described below for the presence or absence of the pJRneu DNA. The percentage of sites with grafts that were also found to be positive for pJRneu by PCR/Southern analyses was then plotted as a function of the grafted numbers of clonogenic cells. A PCR 50 value was calculated to estimate the number of grafted clonogens required to assure that 50% of graft sites were positive for pJRneu.
PCR/Southern analysis
Mammary tissue growth from each graft site was removed at necropsy and the fat tissue surrounding the graft was removed. DNA was extracted from the grafted mammary tissue. Speci®c primers were designed to amplify sequencē anking the neu and SV40 early promoter sequences in pJRneu vector. The upstream primer (5'-TCTCCGCCCC ACCCTTCTCCT-3') was chosen from the neu cDNA region and the downstream primer (5'-CACCCTAACT-GACACACATTC-3') from the SV40 early promoter region. A 1063 bp DNA fragment was the predicted PCR product. Another pair of primers speci®cally ampli®ed a 569 bp DNA fragment anchored in the neo region of pJRneu (the upstream primer: 5'-GTCGCTT GGTCGGTCATTTC-3'; the downstream primer; 5'-AAG GGACTGGCTGCTATTGG-3'). PCR was performed for 20 cycles with Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT). Each cycle consists of denaturation at 948C for 1 min, annealing at 558C for 1 min, and elongation at 728C for 2 min in a thermal cycler (Perkin-Elmer Cetus). The ampli®ed 1063 bp-DNA fragments were analysed on 0.8% agarose gels and then evaluated by Southern hybridization with a 800 bp [a- 32 P]dCTP-labeled probe from the neu cDNA fragment. The other ampli®ed 569 bp-DNA fragments were analysed in the same manner except Southern hybridization with a labeled probe from the neo cDNA sequence. The sensitivity and consistency of detection was monitored by mixing positive with negative DNA in a serial dilution ratio (1/1, 1/10, 1/10 2 , 1/10 3 , 1/10 4 , 1/10 5 ) and assayed as described. Positive DNA was from pJRneu-induced mammary tumors from a previous study (Tai and Gould, 1995) , whereas negative DNA was from normal control mammary glands.
Tumor frequency in graft sites
An average of 750 pJRneu-infected clonogens (7.5610 5 monodispersed pJRneu-infected mammary cells) were transplanted into each graft site of 82 hormonally promoted isologous recipient rats (2 graft sites per rat). Rats were palpated weekly for tumors. All rats were necropsied 6 months after transplantation or when moribund. Tumors were collected and each tumor was divided into aliquots for histopathological characterization and for genomic DNA and RNA isolations. Only histopathologically con®rmed mammary carcinomas in graft sites were included in the data analysis.
Reverse transcriptase-PCR (RT ± PCR) analyses for the expression of pJRneu
Total RNA was isolated from mammary tissue and mammary carcinomas in graft sites by the acid guanidium phenol chloroform extraction method with RNAzol 2 B (TEL-TEST, Inc, Friendwood, TX). One microgram of total RNA was reverse-transcribed using random hexamers and MMLV reverse transcriptase (BRL, Gaithersburg, MD) in a ®nal volume of 20 ml. The resulting cDNA was ampli®ed by 25 cycles of PCR with Taq polymerase under the same condition as described above. Primer pairs were identical to those described above for PCR ampli®cation of genomic DNA samples.
Competitive RT ± PCR
Relative RNA expression level of pJRneu from each pJRneu-containing mammary growth was assayed by a competitive RT ± PRC methodology. This methodology uses competitive ampli®cation of added MIMICs to quantitate relative RNA levels (Siebert and Larrick, 1992; McCulloch et al., 1995; Abe et al., 1995) . A MIMIC is a heterologous DNA fragment with primer templates that are recognized by a pair of gene-speci®c primers so that it mimics the target and is compatibly ampli®ed during PCR. The competitive RT ± PCR methodology was conducted using four sets of primers in the same PCR reaction for each sample, including one set of primers speci®c to the target gene cDNA, pJRneu, one set of primers to a known amount of exogenously added pJRneu MIMIC, one set of primers to an internal standard, 36B4 (rat acidic ribosomal phosphoprotein P0), and one set to a known amount of exogenously added 36B4 MIMIC. In this assay, pJRneu cDNA was competing for ampli®cation with added pJRneu MIMIC and ampli®cation of 36B4 was competing for ampli®cation with added 36B4 MIMIC. This competitive RT ± PCR assay normalizes pJRneu cDNA to an external control (pJRneu MIMIC) and to an internal control (36B4) which itself is normalized to an external control (36B4 MIMIC). Therefore, the relative pJRneu RNA expression level between each positive mammary growth in the graft site can be determined.
MIMICs were generated using the PCR MIMIC Construction kit (Clontech Laboratories, Palo Alto, CA). Construction of MIMICs (Siebert and Larrick, 1993) includes two rounds of PCR ampli®cation. A primary PCR reaction was performed using composite primers that have the target gene primer sequence at the 5' end and heterologous DNA primer sequence on the 3' end. Next, a dilution of the primary PCR reaction was ampli®ed again using only the gene-speci®c primers. The PCR MIMICs were then puri®ed using QIAquick PCR puri®cation Kit (QIAGEN Inc, Chatsworth, CA) and the concentrtion was determined by spectrophotometry. Primer sequences for pJRneu were described as above and ampli®ed a DNA fragment of 1063 bp. Primers for the pJRneu MIMIC were: 5' -TCTCCGCCCCACCCTTCTCCTCGCAAGTGAAATC-TCCTCCG-3' and 5'-CACCCTAACTGACACACATTCTT-GAGTCCATGGGGAGCTTT-3' and ampli®ed a DNA fragment of 596 bp. Primers for 36B4 were: 5'-AAATGCTT-CATTGTGGGAGCAGAC-3' and 5'-TTTTCAGCCAGTG-GGAAGGTGTAG-3' and ampli®ed a DNA fragment of 716 bp. Primers for 36B4 MIMIC were: 5'-AAATGCTT-CATTGTGGGAGCAGACCAAGTTTCGTGAGCTGATT-G-3' and 5'-TTTTCAGCCAGTGGGAAGGTGTAGATTT-GATT-CTGGACCATGGC-3' and ampli®ed a DNA fragment of 432 bp. In a PCR reaction volume of 50 ml, the ®nal concentrations of exogenously added PCR MIMICs were 2.0 ± 4.0610 72 amol/ml of pJRneu MIMIC, 4610 72 amol/ml of 36B4 MIMIC. The PCR pro®le for these competitive RT ± PCR experiments consisted of 2 cycles of 948C for 5 min, 558C for 2 min, 728C for 2 min followed by 20 cycles of 948C for 1 min, 558C for 1 min, 728C for 2 min and a ®nal extension of 728C for 7 min. PCR products were resolved on a 1.6% NuSieve 3 : 1 agarose gel (FMC BioProducts, Rockland, ME) and post-stained with ethidium bromide. Quanti®cation of PCR products was performed on ā uorimager (Molecular Dynamics, Inc., Sunnyvale, CA).
